Epidemiology and treatment of chronic prostatitis: Mersin experience Kronik prostatitin epidemiyolojisi ve tedavisi: Mersin deneyimi
Pamukkale Medical Journal, cilt.19, sa.3, ss.566-573, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.31362/patd.1783689
- Dergi Adı: Pamukkale Medical Journal
- Derginin Tarandığı İndeksler: Scopus, Central & Eastern European Academic Source (CEEAS), TR DİZİN (ULAKBİM), Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.566-573
- Anahtar Kelimeler: Chronic prostatitis, infection, treatment duration, treatment success
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Hatay Mustafa Kemal Üniversitesi Adresli: Evet
Özet
Purpose: Prostatitis is a common condition in men, causing pelvic pain, urinary problems, and sexual dysfunction. Diagnosing and managing of chronic prostatitis can be challenging. In this study we aimed to demonstrate the response of empiric treatment to chronic prostatitis and risk factors to treatment failure. Materials and methods: A total of 39 male patients diagnosed with chronic prostatitis were included in this study. Patients with a history of unsuccessful oral antibiotic therapy for chronic prostatitis were included in the study, whereas patients with urological malignancy or a history of urological interventions were excluded. Researchers evaluated their symptoms, blood tests, urine tests, prostate exams, and imaging studies. They then treated them with various antibiotics and tracked their response. All patients initially received piperacillin-tazobactam at a dose of 4.5 g three times daily and oral doxycycline at a dose of 100 mg twice daily. If the patient had previously received ertapenem plus doxycycline, piperacillin-tazobactam plus doxycycline was administered first; in patients who did not respond, the treatment was switched to imipenem plus doxycycline. Although the number was small, it was observed that some patients who did not respond to ertapenem and doxycycline therapy were switched directly to the imipenem and doxycycline combination. In cases of inadequate response, treatment was increased to intravenous imipenem at a dose of 500 mg four times daily combined with oral doxycycline 100 mg twice daily. In cases where both combination regimens were ineffective, the patient’s treatment was switched to fosfomycin disodium at a dose of 4 g three times daily. Results: While most men presented with lower urinary tract symptoms such as urinary frequency, only a few had positive urine cultures. About 30% of men needed a change in antibiotics during treatment. The subgroup analysis showed that there was no significant difference in treatment groups in terms of recurrence and need for treatment change (p=0.666 and p=0.212). The regression analysis showed that there was no statistically significant association between treatment change and prostate-specific antigen level and prostate volume (p=0.587 and p=0.083, respectively). Treatment response did not seem to be linked to prostate size or prostate-specific antigen levels. Conclusion: Chronic prostatitis is a complex condition with a high rate of treatment failure and recurrence. More research is needed to improve diagnosis and treatment strategies.